致癌轴YAP/MYC/EZH2损害了PTEN瘤抑制活性,增强了肺部瘤性
Federica Lo Sardo1, Chiara Turco1, Beatrice Messina2
1Translational Oncology Research Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
在肺癌中,YAP/TAZ-EZH2-MYC复合体抑制PTEN瘤抑制剂. 针对这一轴恢复PTEN,减少癌症生长,并改善低PTEN水平的患者的预后.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- 瘤抑制剂PTEN (在染色体10中删除的酸酶和张素同类物) 的损失在癌症,特别是肺癌中很常见.
- 降低PTEN的调节,通常没有遗传改变,会增加癌症风险.
- PTEN的表达受到遗传和表观遗传因素的严格调节.
研究的目的:
- 研究调节非小细胞肺癌 (NSCLC) 中PTEN表达的分子机制.
- 确定抑制PTEN的关键调节者,并探索针对该途径的治疗策略.
主要方法:
- 利用分子生物学技术研究NSCLC细胞中的基因调节.
- 分析了患者数据集,以将PTEN表达与临床结果和分子标记者相关联.
- 研究了涉及YAP,TAZ,EZH2和MYC的核综合体的形成和功能.
主要成果:
- YAP,TAZ,EZH2和MYC形成一个复合体,在NSCLC中转录抑制PTEN.
- 这种YAP/TAZ-EZH2-MYC轴的组合向恢复PTEN表达并抑制NSCLC细胞生长.
- 在NSCLC患者中,低PTEN表达与较高的YAP/TAZ,EZH2和MYC水平相关,并预测预后不佳.
结论:
- 在NSCLC中,YAP/TAZ-EZH2-MYC轴在抑制PTEN方面发挥着至关重要的作用.
- 针对这一轴代表着一个有前途的治疗策略,为NSCLC患者减少PTEN表达.
- 恢复PTEN水平提供了改善肺癌治疗结果的潜在途径.
更多相关视频
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
09:55All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System
Published on: December 20, 2021
相关概念视频
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle
PI3K/mTOR/AKT Signaling Pathway
